EASD 2025 15 - 19 September 2025

Oral semaglutide and cardiovascular outcomes by baseline A1c and BMI in people with type 2 diabetes in the SOUL trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Diabetes

Congress oral presentation

GLP-1 RA

Semaglutide (oral)

PHASE 3 (RCT)